Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.
The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach. In oncology, Editas is advancing programs that modify immune cells to enhance anti-tumor activity. Strategic collaborations with pharmaceutical partners, including a 2015 agreement with Allergan (now part of AbbVie) for ocular disease programs and a partnership with Bristol Myers Squibb’s Juno Therapeutics for engineered cell therapy, have supported the expansion of its research footprint.
Editas Medicine operates primarily in North America, conducting clinical studies in the United States and collaborating with academic and clinical research centers globally. The company was co-founded by leading genome scientists, including Feng Zhang of the Broad Institute, and is led by President and CEO James Mullen Jr., whose experience spans leadership roles at several biotechnology and pharmaceutical firms.
With a mission to develop precise, durable treatments for patients with severe genetic diseases, Editas continues to advance its proprietary gene-editing platforms through clinical development and strategic partnerships. The company remains committed to rigorous scientific validation and regulatory engagement as it seeks to bring first-in-class genomic medicines to the clinic.
AI Generated. May Contain Errors.
